GLPwatch

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

NCT05220917 · Active, not recruiting

Last updated 2026-05-28

This study compares four different second-line medication strategies to manage type 2 diabetes and their effects on heart and kidney health in adults with the condition.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.
Type Observational
Participants 781,430 people Planned (estimated).
Who can join Ages 18+ · all sexes
Timeline Started 2021-08 · est. completion 2027-09
Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT05220917 ↗

Description as written by the study sponsor.

To perform an observational analysis to emulate a target trial (i.e., a hypothetical pragmatic trial that would have answered the causal question of interest) comparing the effectiveness and safety of sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide 1 receptor agonists (GLP-1RA), dipeptidyl peptidase-4 inhibitors (DPP-4i), and sulfonylureas (SU), at the class and individual agent level, in head-to-head comparisons in patients with type 2 diabetes (T2D).

Treatments tested

Main thing measuredMACE
SponsorBrigham and Women's Hospital
Conditions studiedCardiovascular Events, Type2 Diabetes, Renal Disease
GLP-1 drugs

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05220917 ↗